
LCTX P/E Ratio
P/E Ratio as of Jun 13, 2025: -10.17
Average-8.13
Median-8.41
Minimum-10.17
Maximum-5.81
-10.17
Past Month-4.27 (72.37%)
The P/E ratio for LCTX is -10.17 as of Jun 13, 2025. This represents a increase of 69.22% compared to its 12-month average P/E ratio of -6.01. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Lineage Cell Therapeutics Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Lineage Cell Therapeutics Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Lineage Cell Therapeutics Inc to industry peers.
Lineage Cell Therapeutics Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Lineage Cell Therapeutics Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Lineage Cell Therapeutics Inc to industry peers.
LCTX P/E Ratio Insights
See Lineage Cell Therapeutics Inc’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares
LCTX P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $0.665 | -8.34 |
May 1, 2025 | $0.504 | -5.19 |
Apr 1, 2025 | $0.411 | -4.23 |
Mar 3, 2025 | $0.5101 | -4.64 |
Feb 3, 2025 | $0.6895 | -6.27 |
Jan 2, 2025 | $0.515 | -4.68 |
LCTX End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -10.17 | +122.54% |
2024 | -4.57 | -43.65% |
2023 | -8.11 | +99.75% |
2022 | -4.06 | -57.58% |
2021 | -9.57 | -24.88% |
2020 | -12.74 | — |
FAQs About Lineage Cell Therapeutics Inc (LCTX) P/E ratio
The latest P/E ratio of LCTX is -10.17, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Lineage Cell Therapeutics Inc’s last 12-month average P/E ratio is -6.01, compared to its current P/E ratio of -10.17. This reflects a increase of 69.22%.
Lineage Cell Therapeutics Inc’s current P/E ratio of -10.17 is higher than its last 12-month average P/E of -6.01. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Lineage Cell Therapeutics Inc’s average P/E ratio over the last 3 years is -7.34. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Lineage Cell Therapeutics Inc’s average P/E ratio over the last 5 years is -11.16. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.